{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:32:51Z","timestamp":1789086771944,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s13555-013-0019-9","type":"journal-article","created":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T04:51:18Z","timestamp":1362199878000},"page":"17-31","source":"Crossref","is-referenced-by-count":24,"title":["Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond"],"prefix":"10.1007","volume":"3","author":[{"given":"C. Lance","family":"Cowey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,2]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archdermatol.2010.19","volume":"146","author":"HW Rogers","year":"2010","unstructured":"Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283\u20137.","journal-title":"Arch Dermatol"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","volume":"353","author":"AI Rubin","year":"2005","unstructured":"Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262\u20139.","journal-title":"N Engl J Med"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D313V4J8VJ","volume":"12","author":"A Wadhera","year":"2006","unstructured":"Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J. 2006;12:7.","journal-title":"Dermatol Online J"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3109\/02841869609083998","volume":"35","author":"K Moeholt","year":"1996","unstructured":"Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma\u2014a review of the literature. Acta Oncol. 1996;35:677\u201382.","journal-title":"Acta Oncol"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archderm.1995.01690140041006","volume":"131","author":"RP Gallagher","year":"1995","unstructured":"Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995;131:157\u201363.","journal-title":"Arch Dermatol"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/014107689709000704","volume":"90","author":"JT Lear","year":"1997","unstructured":"Lear JT, Tan BB, Smith AG, et al. Risk factors for basal cell carcinoma in the UK: case\u2013control study in 806 patients. J R Soc Med. 1997;90:371\u20134.","journal-title":"J R Soc Med"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.TP.0000044135.92850.75","volume":"75","author":"GB Jemec","year":"2003","unstructured":"Jemec GB, Holm EA. Nonmelanoma skin cancer in organ transplant patients. Transplantation. 2003;75:253\u20137.","journal-title":"Transplantation"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2133.2011.10334.x","volume":"165","author":"LJ Parren","year":"2011","unstructured":"Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol. 2011;165:30\u20134.","journal-title":"Br J Dermatol"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJM196005052621803","volume":"262","author":"RJ Gorlin","year":"1960","unstructured":"Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;262:908\u201312.","journal-title":"N Engl J Med"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","volume":"272","author":"RL Johnson","year":"1996","unstructured":"Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668\u201371.","journal-title":"Science"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0092-8674(00)81268-4","volume":"85","author":"H Hahn","year":"1996","unstructured":"Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841\u201351.","journal-title":"Cell"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"217378","DOI":"10.1155\/2011\/217378","volume":"2011","author":"EA Jones","year":"2011","unstructured":"Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in Gorlin syndrome: a review of 202 patients. J Skin Cancer. 2011;2011:217378.","journal-title":"J Skin Cancer"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ng0996-78","volume":"14","author":"MR Gailani","year":"1996","unstructured":"Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14:78\u201381.","journal-title":"Nat Genet"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/34201","volume":"391","author":"J Xie","year":"1998","unstructured":"Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391:90\u20132.","journal-title":"Nature"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/j.1365-2133.2005.06587.x","volume":"152","author":"CM Tilli","year":"2005","unstructured":"Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol. 2005;152:1108\u201324.","journal-title":"Br J Dermatol"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-09-2846","volume":"16","author":"AA Merchant","year":"2010","unstructured":"Merchant AA, Matsui W. Targeting Hedgehog\u2014a cancer stem cell pathway. Clin Cancer Res. 2010;16:3130\u201340.","journal-title":"Clin Cancer Res"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/287795a0","volume":"287","author":"C Nusslein-Volhard","year":"1980","unstructured":"Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980;287:795\u2013801.","journal-title":"Nature"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/0092-8674(93)90627-3","volume":"75","author":"Y Echelard","year":"1993","unstructured":"Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993;75:1417\u201330.","journal-title":"Cell"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0092-8674(93)90628-4","volume":"75","author":"S Krauss","year":"1993","unstructured":"Krauss S, Concordet JP, Ingham PW. A functionally conserved homolog of the Drosophila segment polarity gene hh is expressed in tissues with polarizing activity in zebrafish embryos. Cell. 1993;75:1431\u201344.","journal-title":"Cell"},{"key":"19_CR20","first-page":"445","volume":"19","author":"SW Lee","year":"2007","unstructured":"Lee SW, Moskowitz MA, Sims JR. Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts. Int J Mol Med. 2007;19:445\u201351.","journal-title":"Int J Mol Med"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.mehy.2007.02.021","volume":"69","author":"V Velcheti","year":"2007","unstructured":"Velcheti V. Hedgehog signaling is a potent regulator of angiogenesis in small cell lung cancer. Med Hypotheses. 2007;69:948\u20139.","journal-title":"Med Hypotheses"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-05-2146","volume":"66","author":"C Adolphe","year":"2006","unstructured":"Adolphe C, Hetherington R, Ellis T, Wainwright B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006;66:2081\u20138.","journal-title":"Cancer Res"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1158\/0008-5472.CAN-04-1393","volume":"64","author":"M Athar","year":"2004","unstructured":"Athar M, Li C, Tang X, et al. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res. 2004;64:7545\u201352.","journal-title":"Cancer Res"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1200\/JCO.2010.27.9943","volume":"28","author":"JA Low","year":"2010","unstructured":"Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol. 2010;28:5321\u20136.","journal-title":"J Clin Oncol"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s12272-012-0801-8","volume":"35","author":"JI Yun","year":"2012","unstructured":"Yun JI, Kim HR, Park H, Kim SK, Lee J. Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer. Arch Pharmacol Res. 2012;35:1317\u201333.","journal-title":"Arch Pharmacol Res"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1101\/gad.1025302","volume":"16","author":"JK Chen","year":"2002","unstructured":"Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002;16:2743\u20138.","journal-title":"Genes Dev"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","volume":"361","author":"DD Hoff Von","year":"2009","unstructured":"Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164\u201372.","journal-title":"N Engl J Med"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171\u20139.","journal-title":"N Engl J Med"},{"key":"19_CR29","doi-asserted-by":"crossref","unstructured":"Sekulic A, Migden MR, Oro A, et al. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month ERIVANCE BCC study update. Ann Oncol. 2012;23(Suppl. 9):ix361\u201375.","DOI":"10.1016\/S0923-7534(20)33694-2"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","volume":"366","author":"JY Tang","year":"2012","unstructured":"Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180\u20138.","journal-title":"N Engl J Med"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/ml1000307","volume":"1","author":"S Pan","year":"2010","unstructured":"Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a potent and selective Smoothened antagonist. ACS Med Chem Lett. 2010;1:130\u20134.","journal-title":"ACS Med Chem Lett"},{"key":"19_CR32","doi-asserted-by":"crossref","unstructured":"Rodon Ahnert J, Baselga J, Tawbi HA, et al. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. J Clin Oncol. 2010;28(Suppl.):15s (Abstract 2500).","DOI":"10.1200\/jco.2010.28.15_suppl.2500"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/jid.2011.48","volume":"131","author":"H Skvara","year":"2011","unstructured":"Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131:1735\u201344.","journal-title":"J Invest Dermatol"},{"key":"19_CR34","doi-asserted-by":"crossref","unstructured":"Siu LL, Papadopoulos K, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol. 2010;28(Suppl.):15s (Abstract 2501).","DOI":"10.1200\/jco.2010.28.15_suppl.2501"},{"key":"19_CR35","doi-asserted-by":"crossref","unstructured":"Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324\u20135.","DOI":"10.1001\/archdermatol.2012.2354"},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.1179386","volume":"326","author":"RL Yauch","year":"2009","unstructured":"Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572\u20134.","journal-title":"Science"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/0008-5472.CAN-10-2876","volume":"71","author":"GJ Dijkgraaf","year":"2011","unstructured":"Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71:435\u201344.","journal-title":"Cancer Res"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.0609699104","volume":"104","author":"M Lauth","year":"2007","unstructured":"Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 2007;104:8455\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"19_CR39","doi-asserted-by":"crossref","unstructured":"Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Translat Med. 2010;2:51ra70.","DOI":"10.1126\/scitranslmed.3001599"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-013-0019-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T22:14:04Z","timestamp":1644444844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-013-0019-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s13555-013-0019-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,2]]}}}